Follow the people · Insider
William E. Duke
William E. Duke files insider transactions with the SEC as a chief financial officer of Invivyd (IVVD). We hold 4 disclosed purchases and sales filed since 26 June 2015, 2 of them in the last 90 days.
- Files forIVVD
- Disclosed buys and sells4 in all, 2 in the last 90 days
- Last disclosure18 August 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 September 2023 — 18 August 2026Chief Financial Officer · Invivyd (IVVD)22 Form 4 lines · source: SEC Form 4
- Filed 7 October 2022 — 23 August 2023Chief Financial Officer · Apexigen (APGN)9 Form 4 lines · source: SEC Form 4
- Filed 29 November 2019 — 14 January 2022Chief Financial Officer · Kaleido Biosciences (KLDO)7 Form 4 lines · source: SEC Form 4
- Filed 24 June 2015 — 16 May 2019Chief Financial Officer · Pulmatrix (PULM)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
43 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 102,000 shares of InvivydSEC Form 418 August 2026Common Stock · traded 15 August 2026 · filed 18 August 2026
- ▼ sold on the open market 22,355 shares of InvivydSEC Form 418 August 2026Common Stock · traded 17 August 2026 · filed 18 August 2026
- ▼ sold on the open market 18,425 shares of InvivydSEC Form 418 August 2026Common Stock · traded 18 August 2026 · filed 18 August 2026
- exercised options over 102,000 shares of Invivyd (a derivative holding)SEC Form 418 August 2026Restricted Stock Units · traded 15 August 2026 · filed 18 August 2026
- exercised options over 99,000 shares of InvivydSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- ▼ sold on the open market 19,663 shares of InvivydSEC Form 418 February 2026Common Stock · traded 17 February 2026 · filed 18 February 2026
- ▼ sold on the open market 20,964 shares of InvivydSEC Form 418 February 2026Common Stock · traded 18 February 2026 · filed 18 February 2026
- exercised options over 99,000 shares of Invivyd (a derivative holding)SEC Form 418 February 2026Restricted Stock Units · traded 15 February 2026 · filed 18 February 2026
- exercised options over 99,000 shares of Invivyd (a derivative holding)SEC Form 418 February 2026Restricted Stock Units · traded 15 February 2026 · filed 18 February 2026
- exercised options over 99,000 shares of InvivydSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- ▼ sold on the open market 19,663 shares of InvivydSEC Form 418 February 2026Common Stock · traded 17 February 2026 · filed 18 February 2026
- ▼ sold on the open market 20,964 shares of InvivydSEC Form 418 February 2026Common Stock · traded 18 February 2026 · filed 18 February 2026
- was granted 625,000 shares of Invivyd (a derivative holding)SEC Form 430 January 2026Stock Option (Right to Buy) · traded 29 January 2026 · filed 30 January 2026
- was granted 625,000 shares of Invivyd (a derivative holding)SEC Form 430 January 2026Stock Option (Right to Buy) · traded 29 January 2026 · filed 30 January 2026
- exercised options over 99,000 shares of Invivyd (a derivative holding)SEC Form 419 August 2025Restricted Stock Units · traded 15 August 2025 · filed 19 August 2025
- exercised options over 99,000 shares of InvivydSEC Form 419 August 2025Common Stock · traded 15 August 2025 · filed 19 August 2025
- ▼ sold on the open market 20,013 shares of InvivydSEC Form 419 August 2025Common Stock · traded 18 August 2025 · filed 19 August 2025
- ▼ sold on the open market 29,643 shares of InvivydSEC Form 419 August 2025Common Stock · traded 19 August 2025 · filed 19 August 2025
- was granted 950,000 shares of Invivyd (a derivative holding)SEC Form 419 February 2025Stock Option (Right to Buy) · traded 15 February 2025 · filed 19 February 2025
- was granted 300,000 shares of Invivyd (a derivative holding)SEC Form 419 February 2025Restricted Stock Units · traded 15 February 2025 · filed 19 February 2025
- was granted 200,000 shares of Invivyd (a derivative holding)SEC Form 420 December 2023Stock Option (Right to Buy) · traded 18 December 2023 · filed 20 December 2023
- was granted 750,000 shares of Invivyd (a derivative holding)SEC Form 45 September 2023Stock Option (Right to Buy) · traded 1 September 2023 · filed 5 September 2023
- returned to the issuer 269,848 shares of Apexigen (a derivative holding)SEC Form 425 August 2023Employee Stock Option (right to buy) · traded 23 August 2023 · filed 25 August 2023
- had shares withheld for tax on 26,416 shares of ApexigenSEC Form 425 August 2023Common Stock · traded 23 August 2023 · filed 25 August 2023
- returned to the issuer 128,001 shares of ApexigenSEC Form 425 August 2023Common Stock · traded 23 August 2023 · filed 25 August 2023
- had shares withheld for tax on 4,504 shares of ApexigenSEC Form 423 June 2023Common Stock · traded 15 June 2023 · filed 23 June 2023
- was granted 150,000 shares of ApexigenSEC Form 425 May 2023Common Stock · traded 23 May 2023 · filed 25 May 2023
- had shares withheld for tax on 17,261 shares of ApexigenSEC Form 425 May 2023Common Stock · traded 23 May 2023 · filed 25 May 2023
- had shares withheld for tax on 4,503 shares of ApexigenSEC Form 419 December 2022Common Stock · traded 15 December 2022 · filed 19 December 2022
- was granted 269,848 shares of Apexigen (a derivative holding)SEC Form 411 October 2022Employee Stock Option (right to buy) · traded 7 October 2022 · filed 11 October 2022
- was granted 30,685 shares of ApexigenSEC Form 411 October 2022Common Stock · traded 7 October 2022 · filed 11 October 2022
- was granted 44,990 shares of Kaleido Biosciences (a derivative holding)SEC Form 418 January 2022Restricted Stock Units · traded 14 January 2022 · filed 18 January 2022
- was granted 125,000 shares of Kaleido Biosciences (a derivative holding)SEC Form 418 January 2022Restricted Stock Units · traded 14 January 2022 · filed 18 January 2022
- was granted 60,000 shares of Kaleido Biosciences (a derivative holding)SEC Form 42 September 2021Stock Option (Right to Buy) · traded 1 September 2021 · filed 2 September 2021
- was granted 60,000 shares of Kaleido Biosciences (a derivative holding)SEC Form 42 March 2021Stock Option (Right to Buy) · traded 1 March 2021 · filed 2 March 2021
- was granted 50,000 shares of Kaleido Biosciences (a derivative holding)SEC Form 419 October 2020Stock Option (Right to Buy) · traded 15 October 2020 · filed 19 October 2020
- was granted 50,000 shares of Kaleido Biosciences (a derivative holding)SEC Form 417 April 2020Stock Option (Right to Buy) · traded 15 April 2020 · filed 17 April 2020
- was granted 270,000 shares of Kaleido Biosciences (a derivative holding)SEC Form 42 December 2019Stock Option (Right to Buy) · traded 29 November 2019 · filed 2 December 2019
- was granted 160,000 shares of Pulmatrix (a derivative holding)SEC Form 420 May 2019Stock Option (Right to Buy) · traded 16 May 2019 · filed 20 May 2019
- was granted 850,000 shares of Pulmatrix (a derivative holding)SEC Form 46 June 2018Stock Option (Right to Buy) · traded 5 June 2018 · filed 6 June 2018
- was granted 75,100 shares of Pulmatrix (a derivative holding)SEC Form 422 March 2017Stock Option (Right to Buy) · traded 20 March 2017 · filed 22 March 2017
- was granted 150,200 shares of Pulmatrix (a derivative holding)SEC Form 425 February 2016Stock Option (Right to Buy) · traded 3 February 2016 · filed 25 February 2016
- was granted 235,224 shares of Pulmatrix (a derivative holding)SEC Form 426 June 2015Stock Option (Right to Buy) · traded 24 June 2015 · filed 26 June 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.